May 2, 2017—Hospitals participating in the 340B drug discount program continue to treat more low-income cancer patients than non-340B providers, a study released today found, confirming the 340B program’s longstanding role in helping hospitals meet the needs of their low-income patients. The study by Dobson DaVanzo & Associates found that 340B disproportionate share (DSH) … [Read more...]

May 1, 2017—House and Senate appropriators have agreed on a bill to fund the government through September that level-funds the 340B drug discount program at $10.24 million. … [Read more...]

May 1, 2017—George Sigounas, a Ph.D. professor and cancer researcher at East Carolina University Brody School of Medicine, is the new Administrator of the Health Resources and Services Administration. He assumed the post, which does not require Senate confirmation, today, according to a HRSA spokesperson. … [Read more...]

April 20, 2017—A coalition of hospitals and other safety-net healthcare providers in a federal drug discount program is urging the government to implement a long-overdue regulation to police the pharmaceutical industry. The 340B drug discount program provides healthcare providers with relief from high drug prices. They rely on the savings to fund critical programs for their … [Read more...]

April 5, 2017—Neither the expansion of the 340B drug discount program made by the Affordable Care Act nor changes in Medicare Part B drug reimbursement policy are primary causes of the recent wave of private oncology practice consolidations with hospitals, says a new study in Health Affairs.  Instead, the vertical amalgamation likely is part of a broader trend toward integrated … [Read more...]

March 30, 2017—Congressional Democrats introduced far-ranging legislation yesterday to bring down prescription drug prices. … [Read more...]

March 29, 2017—Healthcare providers in the 340B drug discount program that purchased certain Johnson & Johnson products could be eligible for refunds. … [Read more...]